In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones
- PMID: 9551237
- DOI: 10.1159/000007097
In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones
Abstract
The in vitro inhibitory and bactericidal activities of the investigational fluoroquinolone trovafloxacin were studied and compared with those of five other fluoroquinolones (ciprofloxacin, ofloxacin, pefloxacin, rufloxacin and sparfloxacin) against a wide range of clinical isolates from Italian hospitals. Against gram-positive bacteria, trovafloxacin was overall more active than the other antibiotics tested, including sparfloxacin, another gram-positive-oriented fluoroquinolone, and was active against all ciprofloxacin-resistant streptococci, enterococci, and listeriae, all ciprofloxacin-resistant Staphylococcus aureus isolates and most ciprofloxacin-resistant coagulase-negative staphylococci. Its antistaphylococcal activity was not affected by oxacillin resistance or susceptibility of the isolates, nor was its antipneumococcal activity affected by whether isolates were susceptible or resistant to penicillin. Against gram-negative bacteria, trovafloxacin retained a high potency mostly comparable with that of ciprofloxacin. Rufloxacin and pefloxacin were less active than the other fluoroquinolones against most test strains of both gram-positive and gram-negative organisms. Trovafloxacin minimal bactericidal concentrations usually equalled or exceeded by 2-4 times the minimal inhibitory concentration values, indicating that the compound is overall highly bactericidal.
Similar articles
-
In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.J Antimicrob Chemother. 1997 Sep;40(3):427-31. doi: 10.1093/jac/40.3.427. J Antimicrob Chemother. 1997. PMID: 9338498
-
In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.J Antimicrob Chemother. 1997 Jun;39 Suppl B:15-22. doi: 10.1093/jac/39.suppl_2.15. J Antimicrob Chemother. 1997. PMID: 9222065
-
Comparative antimicrobial activity and spectrum of CP-99,219, a novel fluoroquinolone, tested against ciprofloxacin-resistant clinical isolates.Ir J Med Sci. 1995 Oct-Dec;164(4):271-3. doi: 10.1007/BF02967201. Ir J Med Sci. 1995. PMID: 8522427
-
Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.Eur J Clin Microbiol Infect Dis. 1998 Jun;17(6):405-12. doi: 10.1007/BF01691573. Eur J Clin Microbiol Infect Dis. 1998. PMID: 9758283 Review.
-
The chemistry and biological profile of trovafloxacin.J Antimicrob Chemother. 1997 Jun;39 Suppl B:1-14. doi: 10.1093/jac/39.suppl_2.1. J Antimicrob Chemother. 1997. PMID: 9222064 Review.
Cited by
-
A critical review of the fluoroquinolones: focus on respiratory infections.Drugs. 2002;62(1):13-59. doi: 10.2165/00003495-200262010-00002. Drugs. 2002. PMID: 11790155 Review.
-
Oxidative stress induced by fluoroquinolones on treatment for complicated urinary tract infections in Indian patients.J Young Pharm. 2011 Oct;3(4):304-9. doi: 10.4103/0975-1483.90242. J Young Pharm. 2011. PMID: 22224037 Free PMC article.
-
Ofloxacin otic solution: a review of its use in the management of ear infections.Drugs. 1999 Sep;58(3):509-31. doi: 10.2165/00003495-199958030-00019. Drugs. 1999. PMID: 10493278 Review.
-
Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacin.Antimicrob Agents Chemother. 1999 Jul;43(7):1631-7. doi: 10.1128/AAC.43.7.1631. Antimicrob Agents Chemother. 1999. PMID: 10390214 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources